ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 735.2 | 739.1 | 1328.9 |
| Other income | 59.2 | 77.8 | 61.7 |
| Total income | 794.4 | 816.9 | 1390.6 |
| Profit before exceptional items & tax | 185.6 | 144.1 | 571.9 |
| Profit before tax | 185.6 | 144.1 | 571.9 |
| Net profit | 206.5 | 269.0 | 480.3 |
| Operating margin | 23.4% | 17.6% | 41.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -57.00% |
|---|---|
| Net profit, quarter on quarter | -23.20% |
| Revenue, year on year | -44.70% |
| Operating profit, year on year | -75.20% |
| Operating profit, quarter on quarter | +90.60% |
NSE results filing, NSE: NATCOPHARM. Figures extracted from the filing.
Natco Pharma Ltd: key numbers
- Share price
- ₹810.45
- Market cap
- ₹15,898 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 19.2×Sector 43.7×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Earnings Call Transcript: Key Takeaways
Natco delivered a solid performance with diversified growth in Brazil and South Africa, successfully offsetting the expected decline in Revlimid revenue.
- Call
- Guides 15% growth
Natco Pharma Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹10,194Mn (−30% YoY, +28% QoQ), EBITDA margin 30.4%, PAT ₹2,026Mn. Pipeline and Adcock Ingram stake increase highlighted.
Natco Pharma Dividend
Natco Pharma declared 2nd interim dividend of Rs.1.25 per share for FY26-27. Record date is November 19, 2026; payment begins November 27.
Natco Pharma Q2 FY27 Results: Net Profit ₹202.6 Cr, Down 60.9% YoY
Natco Pharma Ltd reported revenue from operations of ₹967.3 Cr (-29.0% YoY) and net profit of ₹202.6 Cr (-60.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹202.6 Cr · -60.9% YoY
Natco Pharma Share Pledge
Natco Pharma promoter V.C. Nannapaneni pledged 8,50,000 equity shares to Bajaj Financial Securities Limited. The pledge supports the promoter's subscription to the company's Rights Issue.
Natco Pharma Other Announcement
Natco Pharma filed its shareholding pattern with a reporting date of 23 October 2026. Promoter and promoter group hold about 46% of total equity.